The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC).
N. Hashemi Sadraei
No relevant relationships to disclose
C. Jones
No relevant relationships to disclose
A. Tan
No relevant relationships to disclose
P. Elson
No relevant relationships to disclose
T. Mekhail
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
Research Funding - Lilly
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech